Komori
ASKA Pharmaceutical Holdings (4886) · TargetFirst statedLatest Governance (2026-10-01): "Restated"

Long-Term Vision: ASKA VISION 2035

First written in FY2026. 5 of 7 entries say "Restated". Latest entry: 2026-10-01.

7entries
1years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestated2026-03-23 – 2026-10-012026: 72026
Same theme, other companies
Long-term growth vision under ASKA VISION 2035A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2026First statedAnnual report

    「上記を踏まえ、当社グループでは長期ビジョン「ASKA VISION 2035」を策定するとともに、2026年４月から2029年３月末までの中期経営計画2028を開始いたしました。」

    従来の中期経営計画2025に続く長期ビジョンとして、2035年を見据えた「ASKA VISION 2035」を初めて記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Governance of 2026-10-01: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.